Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02708394 · ClinicalTrials.gov registry record · Early Phase 1
Molecular Mechanisms of Antipsychotic-induced Insulin Resistance
A Early Phase 1 study, sponsored by Wayne State University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 31
- Enrollment target
NCT02708394 is a Early Phase 1 study that has completed, run by Wayne State University. The registered enrollment target is 31 participants.
The verdict
NCT02708394, a Early Phase 1 study, has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study will investigate the molecular mechanisms of atypical-antipsychotic induced insulin resistance. This will be accomplished by administering olanzapine or placebo to healthy subjects for 7 days and analyzing genetic and protein changes in peripheral tissues known to play an important role in insulin resistance pathophysiology.
Interventions
- DRUG placebo
- DRUG olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2023-10-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02708394
The ClinicalTrials.gov registry entry for NCT02708394 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wayne State University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02708394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02708394 about?
NCT02708394 is a clinical study titled "Molecular Mechanisms of Antipsychotic-induced Insulin Resistance". This study will investigate the molecular mechanisms of atypical-antipsychotic induced insulin resistance. This will be accomplished by administering olanzapine or placebo to healthy subjects for 7 days and analyzing genetic and protein changes in peripheral tissues known to play an important role i...
What is the current status of trial NCT02708394?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2017-02-01. Estimated completion is 2023-10-01.
What interventions are being tested in trial NCT02708394?
The interventions under investigation include: placebo (DRUG), olanzapine (DRUG).
Who is sponsoring clinical trial NCT02708394?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.